SITE MAP
The person(s) depicted are models used for illustrative purposes only.
- BEXSERO is a vaccine to help prevent invasive disease caused by Neisseria meningitidis serogroup B.6
- BEXSERO is indicated for vaccination of individuals from 2 months of age and older.6
- BEXSERO is a vaccine to help prevent invasive disease caused by Neisseria meningitidis serogroup B.6
- BEXSERO is indicated for vaccination of individuals from 2 months of age and older.6
- BEXSERO is a vaccine to help prevent invasive disease caused by Neisseria meningitidis serogroup B.6
- BEXSERO is indicated for vaccination of individuals from 2 months of age and older.6
- Do not have BEXSERO is you are allergic (hypersensitive) to the active substances or any of the other ingredients in BEXSERO.6,7
- Please note that BEXSERO can only help to protect from invasive meningococcal disease caused by Neisseria meningitidis group B. BEXSERO is not expected to provide protection against all circulating meningococcal group B types.6,7
- Fever may occur following vaccination with BEXSERO. The incidence of fever may be decreased by the use of paracetamol. Before vaccination with BEXSERO, ask your doctor about the risks of fever and how to treat it.6,7
- The safety profile and efficacy of BEXSERO in adults above 50 years of age have not been established.6,7
- Do not have BEXSERO is you are allergic (hypersensitive) to the active substances or any of the other ingredients in BEXSERO.6,7
- Please note that BEXSERO can only help to protect from invasive meningococcal disease caused by Neisseria meningitidis group B. BEXSERO is not expected to provide protection against all circulating meningococcal group B types.6,7
- Fever may occur following vaccination with BEXSERO. The incidence of fever may be decreased by the use of paracetamol. Before vaccination with BEXSERO, ask your doctor about the risks of fever and how to treat it.6,7
- The safety profile and efficacy of BEXSERO in adults above 50 years of age have not been established.6,7
Important safety information
- Do not have BEXSERO is you are allergic (hypersensitive) to the active substances or any of the other ingredients in BEXSERO.6,7
- Please note that BEXSERO can only help to protect from invasive meningococcal disease caused by Neisseria meningitidis group B. BEXSERO is not expected to provide protection against all circulating meningococcal group B types.6,7
- Fever may occur following vaccination with BEXSERO. The incidence of fever may be decreased by the use of paracetamol. Before vaccination with BEXSERO, ask your doctor about the risks of fever and how to treat it.6,7
- The safety profile and efficacy of BEXSERO in adults above 50 years of age have not been established.6,7
References
- Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397–403
- World Health Organization. Meningococcal meningitis. 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/meningitis. Accessed May 2026
- Centers for Disease Control and Prevention. Meningococcal disease. About Meningococcal Disease. Available at: https://www.cdc.gov/meningococcal/about/index.html#cdc_disease_basics_causes_risk_spread-causes (Accessed April 2026)
- IMAC;Factsheet;2026;Meningococcal disease
- Health NZ;Immunisation Handbook 2026 Version 2;2026;1-698
- GlaxoSmithKline NZ, BEXSERO Data Sheet 2024. Available at: https://medsafe.govt.nz/profs/Datasheet/b/bexseroinj.pdf. Accessed May 2026
- GlaxoSmithKline NZ, BEXSERO CMI 2024 Available at: https://www.medsafe.govt.nz/consumers/cmi/b/bexsero.pdf Accessed May 2026
- PHF Science. Invasive Meningococcal Disease Summary: January–December 2025. 2026. Available at: https://www.phfscience.nz/media/qlxh3nie/20260115-invasive-meningococcal-disease-summary.pdf (accessed May 2026)
- Christensen H;Lancet Infect Dis;2010;10;853–61
- NZ Ministry of Health;2019;1-8
- Pharmac Schedule;2026;1-352
- Immunisation Advisory Centre;2025;1-6;Paracetamol use with Bexsero
BEXSERO (Multicomponent meningococcal group B vaccine) is for immunisation against invasive disease caused by N. meningitidis group B from 2 months of age or per official recommendations. BEXSERO is a prescription medicine and is funded as part of the National Immunisation Schedule. See Pharmaceutical Schedule for full funding criteria. BEXSERO is also available for private purchase – normal doctor’s fees apply. One 0.5 ml dose of BEXSERO contains 50 mcg of each N. meningitidis group B component (Neisseria Heparin Binding Antigen fusion protein, Neisseria Adhesin A protein and Factor H Binding Protein fusion protein), as well as 25 mcg outer membrane vesicles from N. meningitidis group B strain NZ98/254. BEXSERO has risks and benefits. Ask your doctor if BEXSERO is right for you. Use strictly as directed. Very common side effects for infants, toddlers, and children (up to 10 years of age) include tenderness at the injection site, fever, and irritability. In adolescents (from 11 years of age) and adults, very common side effects are pain at the injection site, nausea, and headache. If you or your child have side effects, see your doctor. For more information, including full product details, see BEXSERO Consumer Medicine Information at www.medsafe.govt.nz.
For New Zealand Residents only.
Any information provided on the website should be discussed with a healthcare professional (HCP) and does not replace an HCP’s advice.
GSK is not responsible for third-party website content.
©2026 GSK group of companies or its licensor. Trademarks are owned by or licensed to the GSK group of companies. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.
TAPS NP25143-PM-NZ-BEX-WCNT-260001 Date of Approval: July 2026 Date of Expiry July 2028